This information reflects the prior portfolios of Founding Partner Dr. Anna Brady-Estevez during her tenure at institutions such as the National Science Foundation, the Boston Consulting Group (BCG), and the AES Corporation.
We seek to find the next generation of ideas and companies and help them from the earliest stages to move towards growth, value and impact.
Space, Energy, Quantum, Biotech and Resilience.
R&D acceleration, human-AI teaming, cyber resilience.
Pipeline logic + partnerships.
Deep Tech and AI are core to largest markets, opportunities and impacts.
Deep Tech is underfunded in the US, while others (e.g. China) are full speed ahead.
Multi-$B Opportunity to replicate and amplify the nation’s Deep Tech infrastructure; accelerate further & faster with AI.
Anna Brady-Estevez, recommended while Director of strategy at AES
Deputy Chief Scientist of the International Space Station ($150B+ asset) CTO of a $3B+ annual Directorate at NASA, Branch Chief of the US Space Force with work building out the $35B+ Annual Space Force and Air Force Space Industrial Base.
11 Unicorns to date: Team includes founders and inventors of 5 unicorn level companies”, and investors in 6 unicorn level companies.
Team mates include founders and PIs of 6 unicorn level companies.
to date
to date
This information reflects the track record of Anna Brady-Estevez across prior institutions, including the National Science Foundation. The $8.5B in follow-on financing represents capital invested by subsequent investors into companies from her early-stage portfolio. Companies initially supported at the early stage with approximately $250M in funding have gone on to achieve more than $18.7B in total company valuation.
Prior early-stage portfolio funding amounts refer to awards and grants and are publicly available through the NSF Award Search under “Anna Brady,” reflecting activity during her tenure as Program Director (2017–2024). Company valuation data is derived from public records and Pitchbook for private companies that received grants, as of January 2026. No representation is made that these figures will be updated beyond that date.
For the NSF portfolio, illustrative equity cash-on-cash returns may be modeled by using company valuations at the time grants were awarded (or reasonable market assumptions where data is unavailable) and applying dilution assumptions consistent with subsequent funding rounds. Past performance is not indicative of future results. There can be no assurance that future performance will exhibit similar characteristics or returns. Gross TVPI estimates are modeled for the years 2017–2021 and do not account for management fees, performance-based fees, or other expenses that may materially reduce returns. Companies from later years (2022–2025) are earlier in their development cycle, though similar modeling methodologies may be applied.
The total valuation of $18.7B reflects the aggregate market capitalization of companies within Anna Brady-Estevez’s deep technology portfolio, including Fluence, which originated from her corporate work at AES. All other referenced figures relate to the NSF portfolio, where investments were structured as grants.
Large scale infra, AES,Cummins, BCG, NSF & SBA; establishment of NSF AI Research Institutes
American innovators and scientists have historically defined the possible, delivering solutions that generate global abundance. Yet, for too long, the “physical” sciences and deep technology have faced a critical capital gap—slowing the progress the world urgently requires. At American DeepTech, we are investing in the future and closing that gap.
We believe the next era of value creation lies at the intersection of AI Genesis—the application of artificial intelligence to R&D, fundamental science, and physical infrastructure. From autonomous space exploration and oncology breakthroughs to energy resilience and quantum overmatch, we invest in the technologies that secure our future.
We are more than investors; we are inventors and builders who have built companies from the earliest stages to unicorn levels and operated at the highest levels of global infrastructure and national security.
11 Unicorns: Founded 6 and invested in 5 early-stage to “Unicorn” level companies.
$40B in Value: Catalyzed early funding for companies achieving ~$40B in total valuation.
$T+ Scale: transformation work leading to trillion-dollar+ IPO.
$150B Asset for R&D: Leadership at the International Space Station (ISS), focus on commercial R&D.
$35B+ Industrial Base: work to build the US Space Force and Air Force industrial base
National Leadership: Former leaders within the NSF, NASA, Co-chair alongside White House OSTP in US Digital Assets R&D agenda; worked to establish the National AI Research Institutes.
Ongoing Partnerships and Collaboration: NASA, ISS, and work with US Congress
Join us at American DeepTech as we build the future today!
Anna Brady-Estevez, PhD
Founding Partner & Managing Director
American DeepTech
References to long-term track record and operational expertise reflect the professional experience of American DeepTech team members acquired prior to the formation of American DeepTech. Additional details may be provided upon request.
We consistently back high growth companies year after year
Portfolios highlighted prior to 2025 reflect work conducted at organizations preceding the formation of American DeepTech.
[1] Baseload Renewables accepted an award recommendation from Anna Brady-Estevez prior to the formation of Form Energy; however, the awarded funds were not drawn.
[2] Dr. Jamieson was the founder of Impact Biosciences (acquired for approximately $1.1B in cash, with up to $6B in milestone-based consideration). Dr. Jamieson also served as Principal Investigator for Oncternal (VelosBio), including the Phase I trial of zilovertamab, and was an inventor associated with Forty Seven.
[3] Anna Brady-Estevez recommended the investment in AES Energy Storage to the AES executive leadership team in 2011, during a period in which approximately one-third of AES business units were being divested.
[4] Anna Brady-Estevez served briefly as Program Director for Design Therapeutics prior to the transfer of the award.
All remaining portfolio companies referenced were funded through grants awarded by Anna Brady-Estevez during her tenure at the National Science Foundation (NSF).
$40B+ DeepTech: We‘ve funded, founded and grown companies
All figures reflect valuations according to PitchBook unless otherwise stated; $M denotes millions of USD, $B denotes billions of USD; ND indicates not disclosed
For additional context, Dr. Jamieson was the founder and/or inventor of Impact Biomedicines, Visudyne, FortySeven, and VelosBio. All other companies referenced reflect prior funding recommendations and/or project management activities (as Program Manager/Director) led by Anna Brady-Estevez; Fluence was a corporate recommendation at AES. The companies highlighted represent select examples from a broader portfolio of previously funded deeptech and AI companies.
Significant portion at the intersection of AI and Deep Tech
Dr. Jamieson was the founder and/or inventor of Impact Biomedicines, Visudyne, FortySeven, and VelosBio. All other companies referenced reflect prior funding recommendations and/or project management activities (as Program Manager/Director) led by Anna Brady-Estevez; Fluence was a corporate recommendation at AES.